- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.E1348
| Related Targets | HDAC JAK BET Histone Methyltransferase PKC PARP HIF PRMT EZH2 AMPK |
|---|---|
| Other p300/CBP Inhibitors | A-485 Inobrodib (CCS-1477) Curcumin SGC-CBP30 CPI-637 I-CBP112 Histone Acetyltransferase Inhibitor II GNE-049 Anacardic Acid CPI-1612 |
|
In vitro |
DMSO
: 100 mg/mL
(137.76 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 725.86 | Formula | C39H48FN9O4 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1799824-08-0 | -- | Storage of Stock Solutions |
|
|
| Targets/IC50/Ki |
CBP/beta-catenin
0.0484 μM
|
References |
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05607537 | Completed | Healthy Volunteers |
Eisai Limited|Eisai Inc. |
October 17 2022 | Phase 1 |
| NCT05091346 | Recruiting | Melanoma|Carcinoma Hepatocellular|Colorectal Neoplasms |
Eisai Inc.|Merck Sharp & Dohme LLC |
October 27 2021 | Phase 1|Phase 2 |
| NCT04840927 | Withdrawn | Healthy Volunteers |
Eisai Limited|Eisai Inc. |
April 9 2021 | Phase 1 |
| NCT04008797 | Recruiting | Neoplasms|Carcinoma Hepatocellular|Liver Neoplasms|Colorectal Neoplasms|Endometrial Neoplasms |
Eisai Inc. |
July 11 2019 | Phase 1 |
| NCT03996226 | Completed | Food Effect in Healthy Participants |
Eisai Inc. |
June 7 2019 | Phase 1 |
| NCT03833700 | Active not recruiting | Solid Neoplasms|Colorectal Neoplasms|Gastrointestinal Tumors |
Eisai Co. Ltd.|Eisai Inc. |
March 5 2019 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.